Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (7): 642-645.doi: 10.35541/cjd.20191018
Ying Jieya1, Xiang Wenzhong2, Song Xiuzu2
Received:
2019-10-22
Revised:
2020-07-28
Online:
2021-07-15
Published:
2021-07-02
Contact:
Xiang Wenzhong
E-mail:xiangwenzhong@126.com
Ying Jieya, Xiang Wenzhong, Song Xiuzu. Metabolic syndrome and skin diseases[J]. Chinese Journal of Dermatology, 2021, 54(7): 642-645.doi:10.35541/cjd.20191018
[1] | Li R, Li W, Lun Z, et al. Prevalence of metabolic syndrome in Mainland China: a meta⁃analysis of published studies[J]. BMC Public Health, 2016,16:296. doi: 10.1186/s12889⁃016⁃2870⁃y. |
[2] | Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)[J]. JAMA, 2001,285(19):2486⁃2497. doi: 10.1001/jama.285.19.2486. |
[3] | 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中华糖尿病杂志, 2004,12(3):156⁃161. doi: 10.3321/j.issn:1006⁃6187.2004.03. 002. |
[4] | Alberti KG, Zimmet P, Shaw J. Metabolic syndrome⁃⁃a new world⁃wide definition. A consensus statement from the international diabetes federation[J]. Diabet Med, 2006,23(5):469⁃480. doi: 10.1111/j.1464⁃5491.2006.01858.x. |
[5] | Leroith D. Pathophysiology of the metabolic syndrome: implications for the cardiometabolic risks associated with type 2 diabetes[J]. Am J Med Sci, 2012,343(1):13⁃16. doi: 10.1097/MAJ.0b013e31823ea214. |
[6] | 叶丰卉, 晋红中. 脂肪组织原位炎症与代谢[J]. 中华皮肤科杂志, 2017,50(2):149⁃152. doi: 10.3760/cma.j.issn.0412⁃4030. 2017.02.031. |
[7] | 魏伊秋. 慢性炎症与胰岛素抵抗机制关系的研究进展[J]. 临床与病理杂志, 2019,3(39):196⁃201. doi: 10.3978/j.issn.2095⁃6959.2019.03.030. |
[8] | Vona R, Gambardella L, Cittadini C, et al. Biomarkers of oxidative stress in metabolic syndrome and associated diseases[J]. Oxid Med Cell Longev, 2019,2019(2):1⁃19. doi: 10.1155/2019/8267234. |
[9] | Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus[J]. World J Diabetes 2015,6(3):456⁃480. doi: 10.4239/wjd.v6.i3.456. |
[10] | Paschoal RS, Silva DA, Cardili RN, et al. Metabolic syndrome, C⁃reactive protein and cardiovascular risk in psoriasis patients: a cross⁃sectional study[J]. An Bras Dermatol, 2018,93(2):222⁃228. doi: 10.1590/abd1806⁃4841.20186397. |
[11] | Snekvik I, Nilsen TIL, Romundstad PR, et al. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway[J]. Br J Dermatol, 2019,180(1):94⁃99. doi: 10.1111/bjd.16885. |
[12] | Kim HN, Han K, Park YG, et al. Metabolic syndrome is associated with an increased risk of psoriasis: a nationwide population⁃based study[J]. Metab Clin Exp, 2019,99:19⁃24. doi: 10.1016/j.metabol.2019.07.001. |
[13] | Al Mutairi N, Alrqobah D, Haji Hussain N. Prevalence of metabolic syndrome in children with moderate to severe psoriasis treated with TNF inhibitors in comparison to conventional agents[J]. Dermatol Ther, 2018,31(1):e12566. doi: 10.1111/dth.12566. |
[14] | Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon⁃like peptide⁃1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study[J]. Diabetes Res Clin Pract, 2019,150:167⁃173. doi: 10. 1016/j.diabres.2019.03.002. |
[15] | 陈文娟, 彭琛, 丁杨峰, 等. 银屑病共病的研究进展[J]. 中华皮肤科杂志, 2020,53(2):147⁃151. doi: 10.35541/cjd.20190093. |
[16] | Mushtaq S, Dogra D, Dogra N, et al. Cardiovascular and metabolic risk assessment in patients with lichen planus: a tertiary care hospital⁃based study from northern India[J]. Indian Dermatol Online J, 2020,11(2):158⁃166. doi: 10.4103/idoj.IDOJ_ 228_19. |
[17] | Okpala IC, Akinboro AO, Ezejoifor IO, et al. Metabolic syndrome and dyslipidemia among Nigerians with lichen planus: a cross⁃sectional study[J]. Indian J Dermatol, 2019,64(4):303⁃310. doi:10.4103/ijd.IJD_111_18. |
[18] | Kumar SA, Krishnam Raju PV, Gopal KVT, et al. Comorbidities in lichen planus: a case⁃control study in Indian patients[J]. Indian Dermatol Online J, 2019,10(1):34⁃37. doi: 10.4103/idoj.IDOJ_48_18. |
[19] | Aktaş Karabay E, Saltık ZA, Unay Demirel Ö. Evaluation of serum FoxO1, mTORC1, IGF⁃1, IGFBP⁃3 levels and metabolic syndrome components in patients with acne vulgaris: a prospective case⁃control study[J]. Dermatol Ther, 2020:e13887. doi: 10.1111/dth.13887. |
[20] | Nagpal M, De D, Handa S, et al. Insulin resistance and metabolic syndrome in young men with acne[J]. JAMA Demtol, 2016,152(4):399⁃404. doi: 10.1001/jamadermatol.2015.4499. |
[21] | Franik G, Bizoń A, Włoch S, et al. Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome[J]. Eur Rev Med Pharmacol Sci, 2018,22(14):4411⁃4418. doi: 10.26355/eurrev_201807_15491. |
[22] | Akin Belli A, Ozbas Gok S, Akbaba G, et al. The relationship between rosacea and insulin resistance and metabolic syndrome[J]. Eur J Dermatol, 2016,26(3):260⁃264. doi: 10.1684/ejd.2016. 2748. |
[23] | Rainer BM, Fischer AH, Luz Felipe da Silva D, et al. Rosacea is associated with chronic systemic diseases in a skin severity⁃dependent manner: results of a case⁃control study[J]. J Am Acad Dermatol, 2015,73(4):604⁃608. doi: 10.1016/j.jaad.2015. 07.009. |
[24] | Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and metabolic syndrome ⁃ systematic review and adjusted meta⁃analysis[J]. Int J Dermatol, 2019,58(10):1112⁃1117. doi:10. 1111/ijd.14500. |
[25] | Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa[J]. J Am Acad Dermatol, 2019,80(1):114⁃119. doi: 10.1016/j.jaad. 2018.06.063. |
[26] | González⁃López MA, Vilanova I, Ocejo⁃Viñals G, et al. Circulating levels of adiponectin, leptin, resistin and visfatin in non⁃diabetics patients with hidradenitis suppurativa[J]. Arch Dermatol Res, 2019,312(8):595⁃600. doi: 10.1007/s00403⁃019⁃02018⁃4. |
[27] | Swaroop MR, Kumar BM, Sathyanarayana BD, et al. The association of metabolic syndrome and insulin resistance in early⁃onset androgenetic alopecia in males: a case⁃control study[J]. Indian J Dermatol, 2019,64(1):23⁃27. doi: 10.4103/ijd.IJD_724_16. |
[28] | El Sayed MH, Abdallah MA, Aly DG, et al. Association of metabolic syndrome with female pattern hair loss in women: a case⁃control study[J]. Int J Dermatol, 2016,55(10):1131⁃1137. doi: 10.1111/ijd.13303. |
[29] | Misitzis A, Cunha PR, Kroumpouzos G. Skin disease related to metabolic syndrome in women[J]. Int J Womens Dermatol, 2019,5(4):205⁃212. doi: 10.1016/j.ijwd.2019.06.030. |
[30] | Lee S, Lee H, Lee CH, et al. Comorbidities in alopecia areata: a systematic review and meta⁃analysis[J]. J Am Acad Dermatol, 2019,80(2):466⁃477.e16. doi: 10.1016/j.jaad.2018.07.013. |
[31] | Shahidi⁃Dadras M, Bahraini N, Rajabi F, et al. Patients with alopecia areata show signs of insulin resistance[J]. Arch Dermatol Res, 2019,311(7):529⁃533. doi: 10.1007/s00403⁃019⁃01929⁃6. |
[32] | Schiffrin EL. Immune mechanisms in hypertension and vascular injury[J]. Clin Sci, 2014,126(4):267⁃274. doi: 10.1042/CS2013 0407. |
[33] | Shalom G, Dreiher J, Kridin K, et al. Atopic dermatitis and the metabolic syndrome: a cross⁃sectional study of 116 816 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(9):1762⁃1767. doi: 10.1111/jdv.15642. |
[34] | Shalom G, Magen E, Babaev M, et al. Chronic urticaria and the metabolic syndrome: a cross⁃sectional community⁃based study of 11 261 patients[J]. J Eur Acad Dermatol Venereol, 2018,32(2):276⁃281. doi: 10.1111/jdv.14548. |
[35] | Vena GA, Cassano N. The link between chronic spontaneous urticaria and metabolic syndrome[J]. Eur Ann Allergy Clin Immunol, 2017,49(5):208⁃212. doi: 10.23822/EurAnnACI.1764⁃1489.12. |
[36] | Sharma YK, Bansal P, Menon S, et al. Metabolic syndrome in vitiligo patients among a semi⁃urban Maharashtrian population: a case control study[J]. Diabetes Metab Syndr, 2017,11:S77⁃S80. doi: 10.1016/j.dsx.2016.12.009. |
[37] | Tanacan E, Atakan N. Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross⁃sectional study[J]. An Bras Dermatol, 2020,95(2):165⁃172. doi: 10.1016/j.abd.2019.07.006. |
[38] | Seremet S, Gurel MS. Miscellaneous skin disease and the metabolic syndrome[J]. Clin Dermatol, 2018,36(1):94⁃100. doi: 10.1016/j.clindermatol.2017.09.016. |
[39] | Singh SK, Agrawal NK, Vishwakarma AK. Association of acanthosis nigricans and acrochordon with insulin resistance: a cross⁃sectional hospital⁃based study from north India[J]. Indian J Dermatol, 2020,65(2):112⁃117. doi: 10.4103/ijd.IJD_646_18. |
[40] | Hallajzadeh J, Khoramdad M, Izadi N, et al. The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta⁃analysis of observational studies[J]. Lupus, 2018,27(6):899⁃912. doi: 10.1177/0961203317751047. |
[41] | Lesniewska A, Kalińska⁃Bienias A, Kowalewski C, et al. Development of bullous pemphigoid in a patient with psoriasis and metabolic syndrome[J]. Cutis, 2016,98(3):E19. |
[42] | Petermann Smits DR, Wilde B, Kianersi Adegani M, et al. Metabolic syndrome in ANCA⁃associated vasculitis[J]. Rheumatology (Oxford), 2013,52(1):197⁃203. doi: 10.1093/rheumatology/kes345. |
[43] | Nagase T, Akase T, Sanada H, et al. Aging⁃like skin changes in metabolic syndrome model mice are mediated by mineralocorticoid receptor signaling[J]. Aging Cell, 2013,12(1):50⁃57. doi: 10.1111/acel.12017. |
[44] | Nagel G, Bjørge T, Stocks T, et al. Metabolic risk factors and skin cancer in the metabolic syndrome and cancer project (Me⁃Can)[J]. Br J Dermatol, 2012,167(1):59⁃67. doi: 10.1111/j. 1365⁃2133.2012.10974.x. |
[1] | Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482. |
[2] | Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444. |
[3] | China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417. |
[4] | Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475. |
[5] | Ju Qiang, Li Jiaqi. Acne vulgaris revisited: from pathogenesis to treatment strategies [J]. Chinese Journal of Dermatology, 2024, 57(4): 289-294. |
[6] | Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354. |
[7] | Li Jiaqi, Liang Mengchen, Wu Xinyi, Zhang Qiujing, Li Sitong, Mo Xiaohui, Ju Qiang. Staphylococcus epidermidis phylotypes in hair follicles in skin lesions of patients with moderate acne vulgaris: a preliminary study [J]. Chinese Journal of Dermatology, 2024, 57(4): 295-301. |
[8] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
[9] | Wang Yukun, Liu Jie. Application of deep learning in non-neoplastic dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220660-e20220660. |
[10] | Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220795-e20220795. |
[11] | Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274. |
[12] | Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865. |
[13] | Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394. |
[14] | Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448. |
[15] | Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230190-e20230190. |
|